FGF2 and cancer: Moreover, substantial evidence validates the cross-talk among RTKs, including epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) receptors, and their aberrant signaling in cancer.